BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21569010)

  • 1. EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells.
    De Weer A; Van der Meulen J; Rondou P; Taghon T; Konrad TA; De Preter K; Mestdagh P; Van Maerken T; Van Roy N; Jeison M; Yaniv I; Cauwelier B; Noens L; Poirel HA; Vandenberghe P; Lambert F; De Paepe A; Sánchez MG; Odero M; Verhasselt B; Philippé J; Vandesompele J; Wieser R; Dastugue N; Van Vlierberghe P; Poppe B; Speleman F
    Br J Haematol; 2011 Aug; 154(3):337-48. PubMed ID: 21569010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.
    Yoshimi A; Goyama S; Watanabe-Okochi N; Yoshiki Y; Nannya Y; Nitta E; Arai S; Sato T; Shimabe M; Nakagawa M; Imai Y; Kitamura T; Kurokawa M
    Blood; 2011 Mar; 117(13):3617-28. PubMed ID: 21289308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2.
    Gómez-Benito M; Conchillo A; García MA; Vázquez I; Maicas M; Vicente C; Cristobal I; Marcotegui N; García-Ortí L; Bandrés E; Calasanz MJ; Alonso MM; Odero MD
    Br J Cancer; 2010 Oct; 103(8):1292-6. PubMed ID: 20842122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
    Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
    Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
    Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia.
    Vázquez I; Maicas M; Cervera J; Agirre X; Marin-Béjar O; Marcotegui N; Vicente C; Lahortiga I; Gomez-Benito M; Carranza C; Valencia A; Brunet S; Lumbreras E; Prosper F; Gómez-Casares MT; Hernández-Rivas JM; Calasanz MJ; Sanz MA; Sierra J; Odero MD
    Haematologica; 2011 Oct; 96(10):1448-56. PubMed ID: 21750091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical 3q26/MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia.
    Ottema S; Mulet-Lazaro R; Beverloo HB; Erpelinck C; van Herk S; van der Helm R; Havermans M; Grob T; Valk PJM; Bindels E; Haferlach T; Haferlach C; Smeenk L; Delwel R
    Blood; 2020 Jul; 136(2):224-234. PubMed ID: 32219447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The PU.1-Modulated MicroRNA-22 Is a Regulator of Monocyte/Macrophage Differentiation and Acute Myeloid Leukemia.
    Shen C; Chen MT; Zhang XH; Yin XL; Ning HM; Su R; Lin HS; Song L; Wang F; Ma YN; Zhao HL; Yu J; Zhang JW
    PLoS Genet; 2016 Sep; 12(9):e1006259. PubMed ID: 27617961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
    Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-9 is an essential oncogenic microRNA specifically overexpressed in mixed lineage leukemia-rearranged leukemia.
    Chen P; Price C; Li Z; Li Y; Cao D; Wiley A; He C; Gurbuxani S; Kunjamma RB; Huang H; Jiang X; Arnovitz S; Xu M; Hong GM; Elkahloun AG; Neilly MB; Wunderlich M; Larson RA; Le Beau MM; Mulloy JC; Liu PP; Rowley JD; Chen J
    Proc Natl Acad Sci U S A; 2013 Jul; 110(28):11511-6. PubMed ID: 23798388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
    Nishikawa S; Arai S; Masamoto Y; Kagoya Y; Toya T; Watanabe-Okochi N; Kurokawa M
    Blood; 2014 Dec; 124(24):3587-96. PubMed ID: 25298035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
    Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
    Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
    Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
    J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
    Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
    Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EVI1 drives leukemogenesis through aberrant ERG activation.
    Schmoellerl J; Barbosa IAM; Minnich M; Andersch F; Smeenk L; Havermans M; Eder T; Neumann T; Jude J; Fellner M; Ebert A; Steininger M; Delwel R; Grebien F; Zuber J
    Blood; 2023 Feb; 141(5):453-466. PubMed ID: 36095844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.
    Wilson M; Tsakraklides V; Tran M; Xiao YY; Zhang Y; Perkins AS
    J Biol Chem; 2016 Jun; 291(26):13591-607. PubMed ID: 27129260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions.
    Wieser R
    Gene; 2007 Jul; 396(2):346-57. PubMed ID: 17507183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
    Ng HL; Robinson ME; May PC; Innes AJ; Hiemeyer C; Feldhahn N
    Br J Haematol; 2024 Mar; 204(3):945-958. PubMed ID: 38296260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.